<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-04-06T19:33:11.193Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Age Ageing</journal-id><journal-id journal-id-type="iso-abbrev">Age Ageing</journal-id><journal-id journal-id-type="publisher-id">ageing</journal-id><journal-title-group><journal-title>Age and Ageing</journal-title></journal-title-group><issn pub-type="ppub">0002-0729</issn><issn pub-type="epub">1468-2834</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11972633</article-id><article-id pub-id-type="doi">10.1093/ageing/afaf074</article-id><article-id pub-id-type="publisher-id">afaf074</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00280</subject><subject>ageing/4</subject><subject>ageing/7</subject></subj-group></article-categories><title-group><article-title>Risk of adverse outcomes associated with mirtazapine compared to sertraline use among older people living in long-term care facilities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9938-1912</contrib-id><name><surname>Hughes</surname><given-names>Georgina A</given-names></name><!--georgina.hughes@mymail.unisa.edu.au--><aff>
<institution>University of South Australia</institution>, UniSA Clinical &#x00026; Health Sciences, Adelaide, South Australia, <country country="AU">Australia</country></aff><aff>
<institution>Registry of Senior Australians Research Centre</institution>, South Australian Health and Medical Research Institute, Adelaide, South Australia, <country country="AU">Australia</country></aff><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8261-2665</contrib-id><name><surname>Inacio</surname><given-names>Maria C</given-names></name><!--maria.inacio@sahmri.com--><aff>
<institution>Registry of Senior Australians Research Centre</institution>, Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Bedford Park, South Australia, <country country="AU">Australia</country></aff><aff>
<institution>University of South Australia</institution>, UniSA Allied Health &#x00026; Human Performance, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Rowett</surname><given-names>Debra</given-names></name><!--Debra.Rowett@unisa.edu.au--><aff>
<institution>Drug and Therapeutics Information Service</institution>, Southern Adelaide Local Health Network, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1192-4121</contrib-id><name><surname>Caughey</surname><given-names>Gillian E</given-names></name><!--gillian.caughey@sahmri.com--><aff>
<institution>Registry of Senior Australians Research Centre</institution>, South Australian Health and Medical Research Institute, Adelaide, South Australia, <country country="AU">Australia</country></aff><aff>
<institution>Registry of Senior Australians Research Centre</institution>, Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Bedford Park, South Australia, <country country="AU">Australia</country></aff><aff>
<institution>University of South Australia</institution>, UniSA Allied Health &#x00026; Human Performance, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Air</surname><given-names>Tracy</given-names></name><!--tracy.air@sahmri.com--><aff>
<institution>Registry of Senior Australians Research Centre</institution>, South Australian Health and Medical Research Institute, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Catherine E</given-names></name><!--catherine.lang@sahmri.com--><aff>
<institution>Registry of Senior Australians Research Centre</institution>, South Australian Health and Medical Research Institute, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Corlis</surname><given-names>Megan</given-names></name><!--Mcorlis@internode.on.net--><aff>
<institution>Australian Nursing &#x00026; Midwifery Federation SA Branch</institution>, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9059-5209</contrib-id><name><surname>Sluggett</surname><given-names>Janet K</given-names></name><!--janet.sluggett@unisa.edu.au--><aff>
<institution>Registry of Senior Australians Research Centre</institution>, South Australian Health and Medical Research Institute, Adelaide, South Australia, <country country="AU">Australia</country></aff><aff>
<institution>University of South Australia</institution>, UniSA Allied Health &#x00026; Human Performance, Adelaide, South Australia, <country country="AU">Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to: Georgina Anne Hughes, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Email: <email>georgina.hughes@mymail.unisa.edu.au</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-04-06"><day>06</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>06</day><month>4</month><year>2025</year></pub-date><volume>54</volume><issue>4</issue><elocation-id>afaf074</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2024</year></date><date date-type="rev-request"><day>20</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of the British Geriatrics Society.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="afaf074.pdf"/><abstract><title>Abstract</title><sec id="sec3"><title>Background</title><p>Antidepressants are used by 60% of residents of long-term care facilities (LTCFs). Mirtazapine and sertraline are the most commonly used antidepressants, despite little safety information for their use in LTCFs.</p></sec><sec id="sec4"><title>Objective</title><p>To investigate risk of adverse outcomes (falls, fractures, cardiovascular-, dementia-, and delirium-related hospitalisations, all-cause mortality) associated with mirtazapine compared to sertraline use post-LTCF entry.</p></sec><sec id="sec5"><title>Design</title><p>Active new user retrospective cohort study.</p></sec><sec id="sec6"><title>Subjects</title><p>Individuals aged 65&#x02013;105&#x000a0;years entering LTCFs in three Australian states during 1 January 2015 to 31 October 2018, who initiated mirtazapine or sertraline &#x02264;60&#x000a0;days post-LTCF entry, with follow-up to 31 December 2019.</p></sec><sec id="sec7"><title>Methods</title><p>The inverse probability of treatment weighting of individuals&#x02019; propensity scores was used to adjust Cox and Fine&#x02013;Gray regression models to estimate the risk of outcomes of interest associated with mirtazapine compared to sertraline use in LTCFs. Weighted (adjusted) hazard ratios (aHRs), subdistribution hazard ratios and 95% confidence intervals (95% CIs) are presented.</p></sec><sec id="sec8"><title>Results</title><p>A total of 5409 residents initiated mirtazapine (71%, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3837) or sertraline (29%, <italic toggle="yes">n</italic>&#x02009;=&#x02009;1572) post-LTCF entry. After weighting, mirtazapine was associated with a higher risk of mortality (aHR 1.16, 95% CI 1.05&#x02013;1.29) compared to sertraline. The risk of falls and fractures within 90&#x000a0;days was not statistically significantly different between the groups but was lower in mirtazapine users thereafter. No differences in risk of cardiovascular-, dementia- or delirium-related hospitalisations were observed.</p></sec><sec id="sec9"><title>Conclusions</title><p>Compared to sertraline, mirtazapine use is associated with a higher risk of mortality and, after 90&#x000a0;days of use, a lower risk of falls and fractures. This risk of harm should be balanced with limited evidence for effectiveness when considering antidepressant therapy in LTCFs.</p></sec></abstract><kwd-group><kwd>antidepressant</kwd><kwd>mirtazapine</kwd><kwd>sertraline</kwd><kwd>safety</kwd><kwd>long-term care</kwd><kwd>older people</kwd></kwd-group><counts><page-count count="12"/></counts></article-meta></front><body><sec id="sec10h"><title>Key Points</title><list list-type="bullet"><list-item><p>Risk of adverse harms in residents of long-term care facilities (LTCFs) using mirtazapine or sertraline were examined.</p></list-item><list-item><p>Over 5&#x000a0;years, incident mirtazapine use was associated with a 16% higher risk of all-cause mortality compared to sertraline.</p></list-item><list-item><p>Risks of falls and fractures did not differ in the first 90&#x000a0;days of use but were lower in mirtazapine users thereafter.</p></list-item><list-item><p>There were no differences in the risk of cardiovascular-, dementia- or delirium-related hospitalisations.</p></list-item><list-item><p>Risk of harm associated with mirtazapine use compared to sertraline warrants individualised treatment approaches in LTCFs.</p></list-item></list></sec><sec id="sec11"><title>Introduction</title><p>A total of 6 in 10 residents of long-term care facilities (LTCFs) use an antidepressant [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref2" ref-type="bibr">2</xref>]. Mirtazapine, a sedating tetracyclic antidepressant, and sertraline, a selective serotonin reuptake inhibitor (SSRI), are the most common antidepressants used in LTCFs [<xref rid="ref1" ref-type="bibr">1</xref>]. Mirtazapine use more than doubled between 2006 and 2019 [<xref rid="ref1" ref-type="bibr">1</xref>] and is commonly initiated on LTCF entry [<xref rid="ref3" ref-type="bibr">3</xref>]. Mirtazapine is indicated for moderate&#x02013;severe major depression [<xref rid="ref4" ref-type="bibr">4</xref>]; however, potential off-label use for mild depressive symptoms, behaviour, mood or sleep changes (which are common following LTCF entry) has been reported [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref5" ref-type="bibr">5&#x02013;7</xref>]. Substitution of antipsychotics with sedating antidepressants, including mirtazapine, has been described in response to antipsychotic regulations in LTCFs [<xref rid="ref2" ref-type="bibr">2</xref>]. High rates of mirtazapine use are concerning given limited evidence to support its safe and effective use among residents of LTCFs [<xref rid="ref8" ref-type="bibr">8</xref>] who often experience cognitive decline [<xref rid="ref9" ref-type="bibr">9</xref>].</p><p>Systematic reviews of antidepressant safety and effectiveness among older people have used various study designs and report conflicting findings with evidence for efficacy being modest [<xref rid="ref10" ref-type="bibr">10&#x02013;13</xref>]. Three randomised controlled trials (RCTs) among older people [<xref rid="ref14" ref-type="bibr">14&#x02013;16</xref>] had small study sizes (&#x0003c;300 participants) and short follow-ups (16&#x000a0;weeks maximum), used comparators not commonly used for treating depression in LTCFs (i.e. amitriptyline, trazodone, paroxetine [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref5" ref-type="bibr">5</xref>]) and were subject to sponsorship bias with mirtazapine [<xref rid="ref14" ref-type="bibr">14&#x02013;16</xref>]. Two RCTs found mirtazapine is not effective for depression or agitation in dementia [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>].</p><p>Observational studies report an association between mirtazapine use and an increased risk of falls, fractures, cardiovascular events or mortality among older people [<xref rid="ref19" ref-type="bibr">19&#x02013;21</xref>]. Three studies have investigated mirtazapine safety and effectiveness specifically in LTCFs, including an open-label study (<italic toggle="yes">n</italic>&#x02009;=&#x02009;115 residents aged &#x02265;70&#x000a0;years with depression and without severe cognitive impairment) [<xref rid="ref22" ref-type="bibr">22</xref>] and two secondary analyses (<italic toggle="yes">n</italic>&#x02009;=&#x02009;49&#x02013;119) [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>]. All three studies were subject to sponsorship bias, limited follow-up (12&#x000a0;weeks) and did not employ comparator arms, and approximately one-third of the participants discontinued mirtazapine [<xref rid="ref22" ref-type="bibr">22&#x02013;24</xref>]. Of these open-label studies, only one reported a statistically significant reduction in an assessed depression score and the clinical significance is unclear [<xref rid="ref22" ref-type="bibr">22</xref>]. Urinary tract infections, injury and falls were reported in up to one-quarter of the individuals [<xref rid="ref22" ref-type="bibr">22</xref>, <xref rid="ref23" ref-type="bibr">23</xref>].</p><p>Given increasing mirtazapine use, together with a paucity of effectiveness and safety information for residents of LTCFs, leveraging real-world data to examine the risk for adverse outcomes associated with mirtazapine is needed to inform safe antidepressant use in LTCFs. This study investigated the risk of adverse outcomes (i.e. falls, fractures, cardiovascular events, dementia- and delirium-related hospitalisations, and all-cause mortality) among older people initiating mirtazapine following LTCF entry, compared to sertraline. Sertraline was selected as an active comparator as both agents are first-line pharmacological therapies for moderate&#x02013;severe major depression in Australia [<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref25" ref-type="bibr">25</xref>].</p></sec><sec id="sec12"><title>Methods</title><sec id="sec13"><title>Study design and data source</title><p>An active new user propensity score-weighted retrospective cohort study was conducted using de-identified data from the Registry of Senior Australians (ROSA) National Historical Cohort. ROSA, a national data platform, contains integrated health and aged care service utilisation, medical, pharmaceutical, sociodemographic and mortality information for older people (&#x02265;65&#x000a0;years) who were assessed for eligibility or accessed government-subsidised aged care services from 2002 onwards [<xref rid="ref26" ref-type="bibr">26</xref>]. ROSA&#x02019;s core datasets include those within the Australian Institute of Health and Welfare (AIHW) National Aged Care Data Clearinghouse (including the National Death Index), Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) claims records. The PBS dataset includes details of claims for the supply of subsidised medicines in Australia, coded using PBS item codes and mapped to World Health Organization Anatomical Therapeutic Chemical (ATC) codes [<xref rid="ref27" ref-type="bibr">27</xref>]. Hospital and emergency department presentation datasets in public and private hospitals in New South Wales (NSW), Queensland (QLD) and Victoria (VIC) are also linked to ROSA.</p></sec><sec id="sec14"><title>Study setting and cohort</title><p>Non-Indigenous individuals aged 65&#x02013;105&#x000a0;years who entered a LTCF in NSW, QLD or VIC between 1 January 2015 and 31 October 2018 and initiated mirtazapine or sertraline between LTCF entry and&#x02009;&#x02264;60&#x000a0;days after (while in care) were included. Among these individuals, new users were defined as those who were not dispensed an antidepressant in the 120&#x000a0;days before LTCF entry (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>). Individuals were excluded if they were codispensed another antidepressant on the same day, were Department of Veterans&#x02019; Affairs beneficiaries (who can have different MBS-subsidised service access and influence outcome ascertainment) or if they required palliative care on entry. Specific leadership, governance and ethical approvals are required for analysis of Indigenous individuals&#x02019; records and were not part of this study. The index date was the date of first mirtazapine or sertraline dispensing. If individuals entered a LTCF permanently within 1&#x000a0;day of respite care, consecutive (&#x000b1;1&#x000a0;day) records of respite care were linked to determine the LTCF entry date. Residents did not enter a LTCF permanently after 31 December 2019. The cohort included 5409 individuals (<xref rid="f1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="f1"><label>Figure 1</label><caption><p>Flow chart for study cohort selection. <sup>a</sup>There were 632 individuals missing information for Department of Veterans&#x02019; Affairs beneficiary. <sup>b</sup>There were 10&#x000a0;724 individuals missing information for palliative care requirements on LTCF entry.</p></caption><graphic xlink:href="afaf074f1" position="float"/></fig></sec><sec id="sec15"><title>Exposure of interest</title><p>Mirtazapine (ATC N06AX11) or sertraline (ATC N06AB06) dispensings were identified from PBS claims.</p></sec><sec id="sec16"><title>Outcomes of interest</title><p>The outcomes of interest were falls, fractures, cardiovascular events, dementia- and delirium-related hospitalisations and all-cause mortality (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Falls, fractures and dementia- and delirium-related hospitalisations were determined using ROSA&#x02019;s Outcome Monitoring System definitions [<xref rid="ref28" ref-type="bibr">28</xref>]. Cardiovascular events included stroke, myocardial infarction or transient ischemic attack as the principal diagnosis for a hospitalisation or emergency department presentation. A sensitivity analysis also included these death diagnoses in accordance with previous studies using claims data [<xref rid="ref29" ref-type="bibr">29</xref>, <xref rid="ref30" ref-type="bibr">30</xref>].</p><p>In the primary analysis, all individuals had the opportunity for a minimum of 1-year follow-up and were censored at discontinuation of the index antidepressant or dispensing of another antidepressant {median time to antidepressant discontinuation was 164&#x000a0;days [interquartile range (IQR) 50&#x02013;442] for mirtazapine and 151&#x000a0;days [IQR 50&#x02013;443] for sertraline users}, LTCF exit, death or 31 December 2019, whichever occurred first. To determine continuity of exposure, antidepressant discontinuation was defined by a gap in dispensing of two prescription durations after the date the current supply ended [<xref rid="ref31" ref-type="bibr">31</xref>]. The prescription duration was calculated as the period that 75% of the cohort received a repeat supply in 2015 [<xref rid="ref32" ref-type="bibr">32</xref>].</p></sec><sec id="sec17"><title>Covariates</title><p>Potential confounders included in propensity score calculations included individual and medicine-, service- and facility-related factors. Individual factors were determined using aged care eligibility or entry to LTCF assessments and included age at LTCF entry, sex, marital status, preferred language, country of birth, comorbidity score at LTCF entry, levels of assisted daily living, behavioural daily living and complex healthcare needs and health conditions [depression, dementia, diabetes, osteoporosis, malnutrition and history of falls, fractures, cardiovascular events (stroke, myocardial infarction, transient ischaemic attack) or delirium]. RxRisk-V, the medication-based comorbidity score, determined the comorbidity score and identified osteoporosis, dementia, diabetes and malnutrition [<xref rid="ref33" ref-type="bibr">33</xref>]. Medicine-related factors included the number of unique medicines (by ATC code) dispensed in the year before LTCF entry and the use of specific medicine classes &#x02264;120&#x000a0;days before LTCF entry, including antipsychotic, benzodiazepine or zopiclone, opioid, bisphosphonate, lithium, antihypertensive, lipid-lowering, anticoagulant, antiplatelet, anti-arrhythmic, antianginal, loop diuretic, aldosterone antagonist, other heart failure medicine or medicine for Parkinson&#x02019;s disease. System- and facility-related factors included the number of general medical practitioner visits (MBS groups A01, A02, A35), emergency department presentations and unplanned hospitalisations in the year before LTCF entry, LTCF provider type, remoteness and state of residence. Other covariates included time to antidepressant initiation post LTCF-entry (days) and year of study entry.</p></sec><sec id="sec18"><title>Statistical analysis</title><p>The cohort was characterised using descriptive statistics. Logistic regression determined the individuals&#x02019; probability of receiving the studied treatment (a propensity score) using complete case analysis (<italic toggle="yes">n</italic>&#x02009;=&#x02009;182, 3.4% missing data). Inverse probability of treatment weighting (IPTW) was used to estimate the average treatment effect at the population level [<xref rid="ref34" ref-type="bibr">34</xref>]. The balance of weighted propensity scores was assessed using standardised differences after weighting [<xref rid="ref34" ref-type="bibr">34</xref>].</p><p>Time to each outcome for mirtazapine and sertraline users in the weighted population was determined by Kaplan&#x02013;Meier (for all-cause mortality) and cumulative incidence function plots accounting for the competing risk of death (for all other outcomes). Cox proportional hazards models estimated crude and weighted (adjusted) hazard ratios (aHRs) and 95% Wald confidence intervals (CIs) for all-cause mortality and as an additional analysis for all other outcomes. Fine&#x02013;Gray competing risk regression models estimated adjusted subdistribution hazard ratios (aSHRs) and 95% CIs for all outcomes other than mortality [<xref rid="ref35" ref-type="bibr">35</xref>]. To account for nonindependence in observations caused by IPTW-weighting, robust variance estimation (by resident and LTCF) was used in all models. Proportional hazards assumptions were assessed and where violated (for falls and fractures) time-dependent estimates were estimated. Visual examination of these cumulative incidence function plots identified time periods (i.e. &#x02264;90 and&#x02009;&#x0003e;90&#x000a0;days). The Bonferroni correction was used to correct for multiple hypothesis testing in the main analysis (a priori <italic toggle="yes">P</italic>&#x02009;=0.006).</p><p>A sensitivity analysis using an intention-to-treat approach, which followed residents until LTCF exit, death or 31 December 2019, whichever occurred first, was conducted. The risk of each outcome within 90, 365 and 730&#x000a0;days was determined. Principal causes of death (recorded by International Classification of Diseases Tenth Revision, Australian Modification codes) during follow-up were described. SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata v18.0 (StataCorm, College Station, TX, USA) were used for analysis.</p><sec id="sec19"><title>Ethics approval</title><p>This study was approved by the University of South Australia (ref: 200489), AIHW (ref: EO2022/4/1376), South Australian Department for Health &#x00026; Wellbeing (ref: HREC/18/SAH/90) and NSW Population &#x00026; Health Services (ref: 2019/ETH12028) Research Ethics Committees.</p><table-wrap position="float" id="TB1"><label>Table 1</label><caption><p>Baseline characteristics of cohort before and after IPTW and standardised mean differences (SD) after weighting.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Baseline characteristic (<italic toggle="yes">n</italic>,% unless otherwise stated)</th><th rowspan="1" colspan="1">Overall</th><th colspan="2" rowspan="1">Crude</th><th colspan="2" rowspan="1">Weighted<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="2" colspan="1">Weighted SD</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">Mirtazapine</th><th rowspan="1" colspan="1">Sertraline</th><th rowspan="1" colspan="1">Mirtazapine</th><th rowspan="1" colspan="1">Sertraline</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of residents</td><td rowspan="1" colspan="1">5409</td><td rowspan="1" colspan="1">3837 (70.9)</td><td rowspan="1" colspan="1">1572 (29.1)</td><td rowspan="1" colspan="1">3711</td><td rowspan="1" colspan="1">1517</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Year of study entry</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;2015</td><td rowspan="1" colspan="1">1300 (24.0)</td><td rowspan="1" colspan="1">899 (23.4)</td><td rowspan="1" colspan="1">401 (25.5)</td><td rowspan="1" colspan="1">923 (24.9)</td><td rowspan="1" colspan="1">364 (24.0)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;2016</td><td rowspan="1" colspan="1">1397 (25.8)</td><td rowspan="1" colspan="1">973 (25.4)</td><td rowspan="1" colspan="1">424 (27.0)</td><td rowspan="1" colspan="1">964 (26.0)</td><td rowspan="1" colspan="1">410 (27.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;2017</td><td rowspan="1" colspan="1">1444 (26.7)</td><td rowspan="1" colspan="1">1026 (26.7)</td><td rowspan="1" colspan="1">418 (26.6)</td><td rowspan="1" colspan="1">973 (26.2)</td><td rowspan="1" colspan="1">409 (27.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;2018</td><td rowspan="1" colspan="1">1268 (23.4)</td><td rowspan="1" colspan="1">939 (24.5)</td><td rowspan="1" colspan="1">329 (20.9)</td><td rowspan="1" colspan="1">851 (22.9)</td><td rowspan="1" colspan="1">333 (22.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">3047 (56.3)</td><td rowspan="1" colspan="1">2188 (57.0)</td><td rowspan="1" colspan="1">859 (54.6)</td><td rowspan="1" colspan="1">2101 (56.6)</td><td rowspan="1" colspan="1">860 (56.7)</td><td rowspan="1" colspan="1">&#x02212;0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at LTCF entry (median, IQR)</td><td rowspan="1" colspan="1">84 (79&#x02013;89)</td><td rowspan="1" colspan="1">84 (79&#x02013;89)</td><td rowspan="1" colspan="1">84 (78&#x02013;88)</td><td rowspan="1" colspan="1">84 (79&#x02013;89)</td><td rowspan="1" colspan="1">84 (79&#x02013;89)</td><td rowspan="1" colspan="1">&#x02212;0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Born in Australia<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1">3460 (64.0)</td><td rowspan="1" colspan="1">2405 (62.7)</td><td rowspan="1" colspan="1">1055 (67.1)</td><td rowspan="1" colspan="1">2382 (64.2)</td><td rowspan="1" colspan="1">969 (63.9)</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary language is English<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1">4752 (87.9)</td><td rowspan="1" colspan="1">3338 (87.0)</td><td rowspan="1" colspan="1">1414 (89.9)</td><td rowspan="1" colspan="1">3287 (88.6)</td><td rowspan="1" colspan="1">1341 (88.4)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">RxRisk-V comorbidity score on LTCF entry (median, IQR)<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">&#x02212;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Health conditions<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Dementia diagnosis</td><td rowspan="1" colspan="1">2812 (52.0)</td><td rowspan="1" colspan="1">2012 (52.4)</td><td rowspan="1" colspan="1">800 (50.9)</td><td rowspan="1" colspan="1">1940 (52.3)</td><td rowspan="1" colspan="1">794 (52.3)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Depression diagnosis</td><td rowspan="1" colspan="1">3295 (60.9)</td><td rowspan="1" colspan="1">2275 (59.3)</td><td rowspan="1" colspan="1">1020 (64.9)</td><td rowspan="1" colspan="1">2271 (61.2)</td><td rowspan="1" colspan="1">924 (60.9)</td><td rowspan="1" colspan="1">&#x02212;0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of falls</td><td rowspan="1" colspan="1">1255 (23.2)</td><td rowspan="1" colspan="1">883 (23.0)</td><td rowspan="1" colspan="1">372 (23.7)</td><td rowspan="1" colspan="1">858 (23.1)</td><td rowspan="1" colspan="1">350 (23.1)</td><td rowspan="1" colspan="1">&#x02212;0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of fractures</td><td rowspan="1" colspan="1">719 (13.3)</td><td rowspan="1" colspan="1">519 (13.5)</td><td rowspan="1" colspan="1">200 (12.7)</td><td rowspan="1" colspan="1">501 (13.5)</td><td rowspan="1" colspan="1">209 (13.8)</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of transient ischemic attack</td><td rowspan="1" colspan="1">170 (3.1)</td><td rowspan="1" colspan="1">114 (3.0)</td><td rowspan="1" colspan="1">56 (3.6)</td><td rowspan="1" colspan="1">119 (3.2)</td><td rowspan="1" colspan="1">49 (3.2)</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of stroke</td><td rowspan="1" colspan="1">1106 (20.4)</td><td rowspan="1" colspan="1">755 (19.7)</td><td rowspan="1" colspan="1">351 (22.3)</td><td rowspan="1" colspan="1">760 (20.5)</td><td rowspan="1" colspan="1">310 (20.4)</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of myocardial infarction</td><td rowspan="1" colspan="1">226 (4.2)</td><td rowspan="1" colspan="1">151 (3.9)</td><td rowspan="1" colspan="1">75 (4.8)</td><td rowspan="1" colspan="1">159 (4.3)</td><td rowspan="1" colspan="1">68 (4.5)</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of delirium</td><td rowspan="1" colspan="1">404 (7.5)</td><td rowspan="1" colspan="1">298 (7.8)</td><td rowspan="1" colspan="1">106 (6.7)</td><td rowspan="1" colspan="1">278 (7.5)</td><td rowspan="1" colspan="1">118 (7.8)</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Diabetes</td><td rowspan="1" colspan="1">1233 (22.8)</td><td rowspan="1" colspan="1">861 (22.4)</td><td rowspan="1" colspan="1">372 (23.7)</td><td rowspan="1" colspan="1">846 (22.8)</td><td rowspan="1" colspan="1">347 (22.9)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Osteoporosis</td><td rowspan="1" colspan="1">1214 (22.4)</td><td rowspan="1" colspan="1">872 (22.7)</td><td rowspan="1" colspan="1">342 (21.8)</td><td rowspan="1" colspan="1">840 (22.6)</td><td rowspan="1" colspan="1">346 (22.8)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Malnutrition</td><td rowspan="1" colspan="1">119 (2.2)</td><td rowspan="1" colspan="1">91 (2.4)</td><td rowspan="1" colspan="1">28 (1.8)</td><td rowspan="1" colspan="1">81 (2.2)</td><td rowspan="1" colspan="1">35 (2.3)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Activities of daily living level<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;None</td><td rowspan="1" colspan="1">24 (0.4)</td><td rowspan="1" colspan="1">18 (0.5)</td><td rowspan="1" colspan="1">6 (0.4)</td><td rowspan="1" colspan="1">17 (0.5)</td><td rowspan="1" colspan="1">8 (0.5)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Low</td><td rowspan="1" colspan="1">678 (12.5)</td><td rowspan="1" colspan="1">482 (12.6)</td><td rowspan="1" colspan="1">196 (12.5)</td><td rowspan="1" colspan="1">469 (12.6)</td><td rowspan="1" colspan="1">193 (12.7)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Medium</td><td rowspan="1" colspan="1">1692 (31.3)</td><td rowspan="1" colspan="1">1183 (30.8)</td><td rowspan="1" colspan="1">509 (32.4)</td><td rowspan="1" colspan="1">1169 (31.5)</td><td rowspan="1" colspan="1">484 (31.9)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;High</td><td rowspan="1" colspan="1">2975 (55.0)</td><td rowspan="1" colspan="1">2125 (55.4)</td><td rowspan="1" colspan="1">850 (54.1)</td><td rowspan="1" colspan="1">2057 (55.4)</td><td rowspan="1" colspan="1">833 (54.9)</td><td rowspan="1" colspan="1">&#x02212;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Behavioural daily living level<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;None</td><td rowspan="1" colspan="1">173 (3.2)</td><td rowspan="1" colspan="1">133 (3.5)</td><td rowspan="1" colspan="1">40 (2.5)</td><td rowspan="1" colspan="1">122 (3.3)</td><td rowspan="1" colspan="1">51 (3.4)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Low</td><td rowspan="1" colspan="1">492 (9.1)</td><td rowspan="1" colspan="1">340 (8.9)</td><td rowspan="1" colspan="1">152 (9.7)</td><td rowspan="1" colspan="1">341 (9.2)</td><td rowspan="1" colspan="1">137 (9.0)</td><td rowspan="1" colspan="1">&#x02212;0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Medium</td><td rowspan="1" colspan="1">1188 (22.0)</td><td rowspan="1" colspan="1">828 (21.6)</td><td rowspan="1" colspan="1">360 (22.9)</td><td rowspan="1" colspan="1">821 (22.1)</td><td rowspan="1" colspan="1">340 (22.4)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;High</td><td rowspan="1" colspan="1">3516 (65.0)</td><td rowspan="1" colspan="1">2507 (65.3)</td><td rowspan="1" colspan="1">1009 (64.2)</td><td rowspan="1" colspan="1">2427 (65.4)</td><td rowspan="1" colspan="1">989 (65.2)</td><td rowspan="1" colspan="1">&#x02212;0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Complex health care level<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;None</td><td rowspan="1" colspan="1">97 (1.8)</td><td rowspan="1" colspan="1">64 (1.7)</td><td rowspan="1" colspan="1">33 (2.1)</td><td rowspan="1" colspan="1">68 (1.8)</td><td rowspan="1" colspan="1">29 (1.9)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Low</td><td rowspan="1" colspan="1">1201 (22.2)</td><td rowspan="1" colspan="1">835 (21.8)</td><td rowspan="1" colspan="1">366 (23.3)</td><td rowspan="1" colspan="1">823 (22.2)</td><td rowspan="1" colspan="1">335 (22.1)</td><td rowspan="1" colspan="1">&#x02212;0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Medium</td><td rowspan="1" colspan="1">1636 (30.2)</td><td rowspan="1" colspan="1">1156 (30.1)</td><td rowspan="1" colspan="1">480 (30.5)</td><td rowspan="1" colspan="1">1134 (30.6)</td><td rowspan="1" colspan="1">463 (30.5)</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;High</td><td rowspan="1" colspan="1">2435 (45.0)</td><td rowspan="1" colspan="1">1753 (45.7)</td><td rowspan="1" colspan="1">682 (43.4)</td><td rowspan="1" colspan="1">1687 (45.5)</td><td rowspan="1" colspan="1">689 (45.4)</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Marital status<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Widowed</td><td rowspan="1" colspan="1">2181 (40.3)</td><td rowspan="1" colspan="1">1556 (40.6)</td><td rowspan="1" colspan="1">625 (39.8)</td><td rowspan="1" colspan="1">1530 (41.2)</td><td rowspan="1" colspan="1">628 (41.4)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Married or de facto</td><td rowspan="1" colspan="1">2157 (39.9)</td><td rowspan="1" colspan="1">1541 (40.2)</td><td rowspan="1" colspan="1">616 (39.2)</td><td rowspan="1" colspan="1">1505 (40.6)</td><td rowspan="1" colspan="1">616 (40.6)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Divorced</td><td rowspan="1" colspan="1">521 (9.6)</td><td rowspan="1" colspan="1">363 (9.5)</td><td rowspan="1" colspan="1">158 (10.1)</td><td rowspan="1" colspan="1">366 (9.9)</td><td rowspan="1" colspan="1">147 (9.7)</td><td rowspan="1" colspan="1">&#x02212;0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Separated</td><td rowspan="1" colspan="1">48 (0.9)</td><td rowspan="1" colspan="1">35 (0.9)</td><td rowspan="1" colspan="1">13 (0.8)</td><td rowspan="1" colspan="1">34 (0.9)</td><td rowspan="1" colspan="1">12 (0.8)</td><td rowspan="1" colspan="1">&#x02212;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Never married</td><td rowspan="1" colspan="1">399 (7.4)</td><td rowspan="1" colspan="1">273 (7.1)</td><td rowspan="1" colspan="1">126 (8.0)</td><td rowspan="1" colspan="1">278 (7.5)</td><td rowspan="1" colspan="1">113 (7.4)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">State of residence</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;NSW</td><td rowspan="1" colspan="1">2320 (42.9)</td><td rowspan="1" colspan="1">1648 (43.0)</td><td rowspan="1" colspan="1">672 (42.8)</td><td rowspan="1" colspan="1">1589 (42.8)</td><td rowspan="1" colspan="1">649 (42.8)</td><td rowspan="1" colspan="1">&#x02212;0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;VIC</td><td rowspan="1" colspan="1">1855 (34.3)</td><td rowspan="1" colspan="1">1312 (34.2)</td><td rowspan="1" colspan="1">543 (34.5)</td><td rowspan="1" colspan="1">1274 (34.3)</td><td rowspan="1" colspan="1">526 (34.7)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;QLD</td><td rowspan="1" colspan="1">1234 (22.8)</td><td rowspan="1" colspan="1">877 (22.9)</td><td rowspan="1" colspan="1">357 (22.7)</td><td rowspan="1" colspan="1">848 (22.9)</td><td rowspan="1" colspan="1">342 (22.5)</td><td rowspan="1" colspan="1">&#x02212;0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Remoteness of residence<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Major cities</td><td rowspan="1" colspan="1">3829 (70.8)</td><td rowspan="1" colspan="1">2834 (73.9)</td><td rowspan="1" colspan="1">995 (63.3)</td><td rowspan="1" colspan="1">2637 (71.1)</td><td rowspan="1" colspan="1">1079 (71.1)</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Outside major cities</td><td rowspan="1" colspan="1">1567 (29.0)</td><td rowspan="1" colspan="1">996 (26.0)</td><td rowspan="1" colspan="1">571 (36.3)</td><td rowspan="1" colspan="1">1074 (28.9)</td><td rowspan="1" colspan="1">438 (28.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Type of LTCF</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Private</td><td rowspan="1" colspan="1">2415 (44.6)</td><td rowspan="1" colspan="1">1744 (45.5)</td><td rowspan="1" colspan="1">671 (42.7)</td><td rowspan="1" colspan="1">1661 (44.8)</td><td rowspan="1" colspan="1">681 (44.9)</td><td rowspan="1" colspan="1">[ref]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Not for profit</td><td rowspan="1" colspan="1">2717 (50.2)</td><td rowspan="1" colspan="1">1918 (50.0)</td><td rowspan="1" colspan="1">799 (50.8)</td><td rowspan="1" colspan="1">1865 (50.3)</td><td rowspan="1" colspan="1">759 (50.0)</td><td rowspan="1" colspan="1">&#x02212;0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Government</td><td rowspan="1" colspan="1">277 (5.1)</td><td rowspan="1" colspan="1">175 (4.6)</td><td rowspan="1" colspan="1">102 (6.5)</td><td rowspan="1" colspan="1">186 (5.0)</td><td rowspan="1" colspan="1">76 (5.0)</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of GP visits in the year before LTCF entry (median, IQR)</td><td rowspan="1" colspan="1">10 (5&#x02013;17)</td><td rowspan="1" colspan="1">11 (6&#x02013;17)</td><td rowspan="1" colspan="1">10 (5&#x02013;17)</td><td rowspan="1" colspan="1">10 (6&#x02013;17)</td><td rowspan="1" colspan="1">10 (5&#x02013;18)</td><td rowspan="1" colspan="1">&#x02212;0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of ED presentations in the year before LTCF entry (median, IQR)</td><td rowspan="1" colspan="1">1 (1&#x02013;3)</td><td rowspan="1" colspan="1">1 (1&#x02013;3)</td><td rowspan="1" colspan="1">1 (1&#x02013;3)</td><td rowspan="1" colspan="1">1 (1&#x02013;3)</td><td rowspan="1" colspan="1">1 (1&#x02013;3)</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of unplanned hospitalisations in the year before LTCF entry (median, IQR)</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of unique medicines dispensed in the year before LTCF entry (median, IQR)<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></td><td rowspan="1" colspan="1">9 (5&#x02013;14)</td><td rowspan="1" colspan="1">9 (6&#x02013;14)</td><td rowspan="1" colspan="1">9 (5&#x02013;14)</td><td rowspan="1" colspan="1">9 (6&#x02013;14)</td><td rowspan="1" colspan="1">9 (5&#x02013;14)</td><td rowspan="1" colspan="1">&#x02212;0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">Specific classes of medicines dispensed in the 120&#x000a0;days before LTCF entry</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Antipsychotic</td><td rowspan="1" colspan="1">567 (10.5)</td><td rowspan="1" colspan="1">425 (11.1)</td><td rowspan="1" colspan="1">142 (9.0)</td><td rowspan="1" colspan="1">386 (10.4)</td><td rowspan="1" colspan="1">154 (10.2)</td><td rowspan="1" colspan="1">&#x02212;0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Benzodiazepine or zopiclone</td><td rowspan="1" colspan="1">989 (18.3)</td><td rowspan="1" colspan="1">768 (20.0)</td><td rowspan="1" colspan="1">221 (14.1)</td><td rowspan="1" colspan="1">683 (18.4)</td><td rowspan="1" colspan="1">278 (18.3)</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Medicine for Parkinson&#x02019;s disease</td><td rowspan="1" colspan="1">260 (4.8)</td><td rowspan="1" colspan="1">192 (5.0)</td><td rowspan="1" colspan="1">68 (4.3)</td><td rowspan="1" colspan="1">179 (4.8)</td><td rowspan="1" colspan="1">78 (5.1)</td><td rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Opioid</td><td rowspan="1" colspan="1">1271 (23.5)</td><td rowspan="1" colspan="1">940 (24.5)</td><td rowspan="1" colspan="1">331 (21.1)</td><td rowspan="1" colspan="1">870 (23.4)</td><td rowspan="1" colspan="1">361 (23.8)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Bisphosphonate</td><td rowspan="1" colspan="1">311 (5.7)</td><td rowspan="1" colspan="1">234 (6.1)</td><td rowspan="1" colspan="1">77 (4.9)</td><td rowspan="1" colspan="1">214 (5.8)</td><td rowspan="1" colspan="1">91 (6.0)</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Antiplatelet</td><td rowspan="1" colspan="1">920 (17.0)</td><td rowspan="1" colspan="1">640 (16.7)</td><td rowspan="1" colspan="1">280 (17.8)</td><td rowspan="1" colspan="1">634 (17.1)</td><td rowspan="1" colspan="1">264 (17.4)</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Anticoagulant</td><td rowspan="1" colspan="1">1129 (20.9)</td><td rowspan="1" colspan="1">819 (21.3)</td><td rowspan="1" colspan="1">310 (19.7)</td><td rowspan="1" colspan="1">777 (20.9)</td><td rowspan="1" colspan="1">320 (21.1)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Antianginal</td><td rowspan="1" colspan="1">427 (7.9)</td><td rowspan="1" colspan="1">300 (7.8)</td><td rowspan="1" colspan="1">127 (8.1)</td><td rowspan="1" colspan="1">297 (8.0)</td><td rowspan="1" colspan="1">124 (8.2)</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Anti-arrhythmic</td><td rowspan="1" colspan="1">504 (9.3)</td><td rowspan="1" colspan="1">369 (9.6)</td><td rowspan="1" colspan="1">135 (8.6)</td><td rowspan="1" colspan="1">351 (9.5)</td><td rowspan="1" colspan="1">140 (9.2)</td><td rowspan="1" colspan="1">&#x02212;0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Lipid lowering</td><td rowspan="1" colspan="1">2040 (37.7)</td><td rowspan="1" colspan="1">1445 (37.7)</td><td rowspan="1" colspan="1">595 (37.8)</td><td rowspan="1" colspan="1">1401 (37.8)</td><td rowspan="1" colspan="1">577 (38.0)</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Antihypertensive</td><td rowspan="1" colspan="1">3229 (59.7)</td><td rowspan="1" colspan="1">2316 (60.4)</td><td rowspan="1" colspan="1">913 (58.1)</td><td rowspan="1" colspan="1">2222 (59.9)</td><td rowspan="1" colspan="1">907 (59.8)</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Furosemide</td><td rowspan="1" colspan="1">1061 (19.6)</td><td rowspan="1" colspan="1">769 (20.0)</td><td rowspan="1" colspan="1">292 (18.6)</td><td rowspan="1" colspan="1">731 (19.7)</td><td rowspan="1" colspan="1">300 (19.8)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Aldosterone antagonist</td><td rowspan="1" colspan="1">289 (5.3)</td><td rowspan="1" colspan="1">211 (5.5)</td><td rowspan="1" colspan="1">78 (5.0)</td><td rowspan="1" colspan="1">195 (5.3)</td><td rowspan="1" colspan="1">80 (5.3)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Other medicines for heart failure</td><td rowspan="1" colspan="1">9 (0.2)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">&#x02212;0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Time to antidepressant initiation (days) [median, IQR]</td><td rowspan="1" colspan="1">18 (3&#x02013;37)</td><td rowspan="1" colspan="1">17 (3&#x02013;37)</td><td rowspan="1" colspan="1">20 (4&#x02013;39)</td><td rowspan="1" colspan="1">18 (3&#x02013;38)</td><td rowspan="1" colspan="1">19 (3&#x02013;37)</td><td rowspan="1" colspan="1">&#x02212;0.004</td></tr></tbody></table><table-wrap-foot><p>SD, standardised mean differences; N/A, not available (due to low counts); GP, general practitioner; ED, emergency department.</p><p>Lithium dispensed in the 4&#x000a0;months before LTCF entry was assessed but not reported due to low counts. There were 432 (8.0%) of individuals without PBS medicines dispensed 6&#x000a0;months before LTCF entry and 595 (11.0%) 4&#x000a0;months before LTCF entry.</p><fn id="tblfn1"><p>
<sup>a</sup>IPTW cohort does not include <italic toggle="yes">n</italic>&#x02009;=&#x02009;182 individuals with missing data for determining propensity scores (complete case analysis).</p></fn><fn id="tblfn2"><p>
<sup>b</sup>Missing data <italic toggle="yes">n</italic> (%): country of birth 20 (0.4), primary language 28 (0.5), entry to care assessment 40 (0.7), aged care eligibility assessment 268 (5.0), remoteness 13 (0.2) and marital status 103 (1.9).</p></fn><fn id="tblfn3"><p>
<sup>c</sup>Number of unique medicines and comorbidity score do not include antidepressants.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="sec20"><title>Results</title><p>There were 5409 individuals from 1666 LTCFs who initiated mirtazapine (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3837, 70.9%) or sertraline (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1572, 29.1%) within &#x02264;60&#x000a0;days of LTCF entry, with a median age of 84&#x000a0;years (IQR 79&#x02013;89). <xref rid="TB1" ref-type="table">Table 1</xref> shows the IPTW cohorts and standardised differences. Residents were followed up to 5&#x000a0;years, with overall median follow-up of 258&#x000a0;days (IQR 70&#x02013;634), 252&#x000a0;days (IQR 68&#x02013;622) among mirtazapine (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3711) and 279&#x000a0;days (IQR 72&#x02013;672) among sertraline (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1517) users in the IPTW cohort (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5228).</p><sec id="sec21"><title>Falls and fractures</title><p>The cumulative incidence of falls, accounting for the competing risk of death, was 34.5% (95% CI 31.5&#x02013;37.5) for mirtazapine and 43.0% (95% CI 35.0&#x02013;50.8) for sertraline users (<xref rid="f2" ref-type="fig">Figure 2</xref>). The cumulative incidence of fractures was 18.5% (95% CI 15.3&#x02013;21.9) in mirtazapine and 25.7% (95% CI 18.6&#x02013;33.4) in sertraline users (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2</xref>). There were no statistically significant differences in the risk of falls (aSHR 0.99, 95%&#x000a0;CI 0.80&#x02013;1.23, <italic toggle="yes">P</italic>&#x02009;=0.938) or fractures (aSHR 0.93, 95% CI 0.66&#x02013;1.31, <italic toggle="yes">P</italic>&#x02009;= 0.673) between mirtazapine and sertraline users in the first 90&#x000a0;days. There was a lower risk of falls (aSHR 0.74, 95% CI 0.63&#x02013;0.87, <italic toggle="yes">P</italic>&#x02009;&#x0003c;0.001) and fractures (aSHR 0.64, 95% CI 0.52&#x02013;0.80, <italic toggle="yes">P</italic>&#x02009;&#x0003c;0.001) in mirtazapine users after 90&#x000a0;days, compared to sertraline (<xref rid="TB2" ref-type="table">Table 2</xref>).</p><fig position="float" id="f2"><label>Figure 2</label><caption><p>Cumulative incidence of falls and competing risk of death among the weighted cohorts, by antidepressant type. Cumulative incidence of falls, and death as the competing event, is plotted. Dotted vertical line at 90&#x000a0;days for time-varying effects. Plot truncated to 4&#x000a0;years due to low numbers at risk thereafter. Numbers at risk of the IPTW cohort are listed by exposure group at bottom of plot.</p></caption><graphic xlink:href="afaf074f2" position="float"/></fig><table-wrap position="float" id="TB2"><label>Table 2</label><caption><p>Number of individuals experiencing adverse outcomes and associated risk among residents initiating mirtazapine versus sertraline.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Outcome</th><th colspan="2" rowspan="1">Crude (<italic toggle="yes">n</italic>,%)</th><th colspan="2" rowspan="1">Weighted<xref rid="tblfn4" ref-type="table-fn"><sup>a</sup></xref> (<italic toggle="yes">n</italic>,%)</th><th rowspan="2" align="left" colspan="1">Weighted aHR (95% CI, <italic toggle="yes">P</italic>)<xref rid="tblfn4" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="2" align="left" colspan="1">aSHR (95% CI, <italic toggle="yes">P</italic>)<xref rid="tblfn4" ref-type="table-fn">*</xref></th></tr><tr><th align="left" rowspan="1" colspan="1">Mirtazapine (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3837)</th><th align="left" rowspan="1" colspan="1">Sertraline (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1572)</th><th align="left" rowspan="1" colspan="1">Mirtazapine (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3711)</th><th align="left" rowspan="1" colspan="1">Sertraline (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1517)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fall</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Overall</td><td rowspan="1" colspan="1">775 (20.2)</td><td rowspan="1" colspan="1">373 (23.7)</td><td rowspan="1" colspan="1">746 (20.1)</td><td rowspan="1" colspan="1">363 (23.9)</td><td rowspan="1" colspan="1">0.86 (0.75&#x02013;0.97), 0.018</td><td rowspan="1" colspan="1">
<bold>0.82 (0.72&#x02013;0.94), 0.003</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;&#x02264;90&#x000a0;days</td><td rowspan="1" colspan="1">297 (7.7)</td><td rowspan="1" colspan="1">126 (8.0)</td><td rowspan="1" colspan="1">285 (7.7)</td><td rowspan="1" colspan="1">118 (7.8)</td><td rowspan="1" colspan="1">1.01 (0.81&#x02013;1.25), 0.961</td><td rowspan="1" colspan="1">0.99 (0.80&#x02013;1.23), 0.938</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;&#x0003e;90&#x000a0;days</td><td rowspan="1" colspan="1">478 (12.5)</td><td rowspan="1" colspan="1">247 (15.7)</td><td rowspan="1" colspan="1">461 (12.4)</td><td rowspan="1" colspan="1">245 (16.2)</td><td rowspan="1" colspan="1">
<bold>0.78 (0.67&#x02013;0.92), 0.003</bold>
</td><td rowspan="1" colspan="1">
<bold>0.74 (0.63&#x02013;0.87), &#x0003c;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Fracture</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Overall</td><td rowspan="1" colspan="1">361 (9.4)</td><td rowspan="1" colspan="1">193 (12.3)</td><td rowspan="1" colspan="1">343 (9.2)</td><td rowspan="1" colspan="1">194 (12.8)</td><td rowspan="1" colspan="1">
<bold>0.74 (0.62&#x02013;0.89), 0.001</bold>
</td><td rowspan="1" colspan="1">
<bold>0.71 (0.59&#x02013;0.85), &#x0003c;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;&#x02264;90&#x000a0;days</td><td rowspan="1" colspan="1">109 (2.8)</td><td rowspan="1" colspan="1">49 (3.1)</td><td rowspan="1" colspan="1">104 (2.8)</td><td rowspan="1" colspan="1">46 (3.0)</td><td rowspan="1" colspan="1">0.94 (0.67&#x02013;1.34), 0.739</td><td rowspan="1" colspan="1">0.93 (0.66&#x02013;1.31), 0.673</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;&#x0003e;90&#x000a0;days</td><td rowspan="1" colspan="1">252 (6.6)</td><td rowspan="1" colspan="1">144 (9.2)</td><td rowspan="1" colspan="1">239 (6.4)</td><td rowspan="1" colspan="1">148 (9.8)</td><td rowspan="1" colspan="1">
<bold>0.68 (0.55&#x02013;0.84), &#x0003c;0.001</bold>
</td><td rowspan="1" colspan="1">
<bold>0.64 (0.52&#x02013;0.80), &#x0003c;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular event</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Main analysis</td><td rowspan="1" colspan="1">187 (4.9)</td><td rowspan="1" colspan="1">79 (5.0)</td><td rowspan="1" colspan="1">183 (4.9)</td><td rowspan="1" colspan="1">71 (4.7)</td><td rowspan="1" colspan="1">1.11 (0.84&#x02013;1.45), 0.459</td><td rowspan="1" colspan="1">1.06 (0.81&#x02013;1.39), 0.684</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Sensitivity analysis<xref rid="tblfn5" ref-type="table-fn"><sup><bold>b</bold></sup></xref></td><td rowspan="1" colspan="1">316 (8.2)</td><td rowspan="1" colspan="1">127 (8.1)</td><td rowspan="1" colspan="1">314 (8.5)</td><td rowspan="1" colspan="1">120 (7.9)</td><td rowspan="1" colspan="1">1.12 (0.91&#x02013;1.39), 0.290</td><td rowspan="1" colspan="1">1.07 (0.87&#x02013;1.33), 0.513</td></tr><tr><td align="left" rowspan="1" colspan="1">Dementia</td><td rowspan="1" colspan="1">126 (3.3)</td><td rowspan="1" colspan="1">50 (3.2)</td><td rowspan="1" colspan="1">124 (3.3)</td><td rowspan="1" colspan="1">51 (3.4)</td><td rowspan="1" colspan="1">1.03 (0.74&#x02013;1.44), 0.862</td><td rowspan="1" colspan="1">1.00 (0.71&#x02013;1.39), 0.975</td></tr><tr><td align="left" rowspan="1" colspan="1">Delirium</td><td rowspan="1" colspan="1">212 (5.5)</td><td rowspan="1" colspan="1">72 (4.6)</td><td rowspan="1" colspan="1">195 (5.4)</td><td rowspan="1" colspan="1">68 (4.5)</td><td rowspan="1" colspan="1">1.22 (0.92&#x02013;1.62), 0.172</td><td rowspan="1" colspan="1">1.17 (0.88&#x02013;1.56), 0.267</td></tr><tr><td align="left" rowspan="1" colspan="1">All-cause mortality</td><td rowspan="1" colspan="1">1471 (38.3)</td><td rowspan="1" colspan="1">556 (35.4)</td><td rowspan="1" colspan="1">1429 (38.5)</td><td rowspan="1" colspan="1">531 (35.0)</td><td rowspan="1" colspan="1">
<bold>1.16 (1.05&#x02013;1.29), 0.004</bold>
</td><td rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><p>N/A, not applicable. Statistically significant results are shown in bold.</p><fn id="tblfn4"><p>
<sup>a</sup>IPTW cohort does not include <italic toggle="yes">n</italic>&#x02009;=&#x02009;182 individuals with missing data for determining propensity scores (complete case analysis).</p></fn><fn id="tblfn5"><p>
<sup>b</sup>Sensitivity analysis for ascertaining cardiovascular events also included cardiovascular event death diagnoses.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec22"><title>Cardiovascular events</title><p>The cumulative incidence of cardiovascular events, accounting for the competing risk of death was 9.0% (95% CI 7.2&#x02013;11.1) for mirtazapine and 8.6% (95% CI 6.1&#x02013;11.5) for sertraline users (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3</xref>). There was no statistically significant difference in risk of cardiovascular events between mirtazapine and sertraline (aSHR 1.06, 95% CI 0.81&#x02013;1.39, <italic toggle="yes">P</italic>&#x02009;=0.684).</p></sec><sec id="sec23"><title>Dementia- and delirium-related hospitalisations</title><p>The cumulative incidence of dementia-related hospitalisations was 4.5% (95% CI 3.7&#x02013;5.5) for mirtazapine, and 5.3% (95% CI 3.9&#x02013;7.0) for sertraline users, accounting for the competing risk of death (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 4</xref>). The cumulative incidence of delirium-related hospitalisations was 8.8% (95% CI 7.2&#x02013;10.5) for mirtazapine and 7.2% (95% CI 5.4&#x02013;9.2) among sertraline users (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 5</xref>). There was no statistically significant difference in risk of dementia-related (aSHR 1.00, 95% CI 0.71&#x02013;1.39, <italic toggle="yes">P</italic>&#x02009;=0.975) or delirium-related (aSHR 1.17, 95% CI 0.88&#x02013;1.56, <italic toggle="yes">P</italic>&#x02009;=0.267) hospitalisations between mirtazapine and sertraline users.</p></sec><sec id="sec24"><title>All-cause mortality</title><p>The proportion of people who died during follow-up was 38.5% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1429) among mirtazapine and 35.0% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;531) among sertraline users. There was a higher risk of all-cause mortality among mirtazapine users, compared to sertraline (aHR 1.16, 95% CI 1.05&#x02013;1.29, <italic toggle="yes">P</italic>&#x02009;=0.004; <xref rid="f3" ref-type="fig">Figure 3</xref>). Primary causes for death were similar between groups and comprised neoplasms, mental and behavioural disorders, and nervous, circulatory and respiratory system disorders among 80.3% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1143) of deaths for mirtazapine and 80.1% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;427) for sertraline users (<xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 2</xref> and <xref rid="sup1" ref-type="supplementary-material">3</xref>).</p><fig position="float" id="f3"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier survival plot with 95% confidence bands for time to all-cause mortality among the weighted cohorts, by antidepressant type. Plot truncated to 3&#x000a0;years due to low numbers at risk thereafter. Numbers at risk of the IPTW cohort are listed by exposure group at bottom of plot.</p></caption><graphic xlink:href="afaf074f3" position="float"/></fig></sec><sec id="sec25"><title>Sensitivity analyses</title><p>The intention-to-treat estimates were of the same direction, strength and statistical significance (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). Most risk estimates were comparable at 90, 365 and 730&#x000a0;days, except for falls and fractures that were not statistically significant within 90&#x000a0;days (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>). The addition of deaths records to ascertain cardiovascular events showed negligible differences.</p></sec></sec><sec id="sec26"><title>Discussion</title><p>This study among residents of LTCFs found mirtazapine use following LTCF entry was associated with a 16% higher risk of all-cause mortality, compared to sertraline, and a lower risk of falls and fractures after 90&#x000a0;days. There was no difference in risk of falls and fractures in the short-term (&#x02264;90&#x000a0;days), or cardiovascular-, dementia- or delirium-related hospitalisations during any period. These findings provide clinicians with new evidence about adverse outcomes that are important to older people living in LTCFs [<xref rid="ref36" ref-type="bibr">36</xref>], to inform shared decisions with residents and their families when considering treatment options for depression.</p><p>There are no prior LTCF-specific studies examining the association between mirtazapine use and mortality. In the general population, a higher risk of mortality has been observed with mirtazapine use compared to no antidepressant use [<xref rid="ref19" ref-type="bibr">19</xref>] or other antidepressant types or classes [<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref21" ref-type="bibr">21</xref>, <xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref38" ref-type="bibr">38</xref>]. However, individuals without dementia or aged &#x02265;80&#x000a0;years had a lower risk of mortality compared to citalopram users [<xref rid="ref21" ref-type="bibr">21</xref>]. Another study found adults (<italic toggle="yes">n</italic>&#x02009;=&#x02009;25&#x000a0;598) who augmented their treatment for depression or switched from an SSRI to mirtazapine had a higher risk of all-cause mortality within 2&#x000a0;years compared to initiating another SSRI and a higher risk &#x02265;2&#x000a0;years when compared to another SSRI, amitriptyline or venlafaxine [<xref rid="ref39" ref-type="bibr">39</xref>]. There was also a higher risk of respiratory- and neoplasm-related mortality associated with mirtazapine compared to another SSRI within 2&#x000a0;years [<xref rid="ref39" ref-type="bibr">39</xref>]. These were common reasons for death in our analysis. However, causes of death were similar between mirtazapine and sertraline users and there was no difference in risk of cardiovascular events. It is possible that unmeasured confounding or prescribing and deprescribing cascades post-LTCF entry influenced the higher risk of mortality associated with mirtazapine compared to sertraline. Further investigation is needed to understand cause-specific mortality risks. The 16% higher risk of all-cause mortality associated with mirtazapine is concerning given it is the fifth most common medicine supplied in Australian LTCFs [<xref rid="ref40" ref-type="bibr">40</xref>] and received by one in five residents [<xref rid="ref1" ref-type="bibr">1</xref>]. The potential population-level risk of harm associated with mirtazapine use in LTCFs is considerable and clinicians should consider this in the context of the limited evidence of its effectiveness [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>].</p><p>There was no statistically significant difference in risk of falls or fractures (short-term), cardiovascular-, dementia- or delirium-related hospitalisations between mirtazapine and sertraline use in LTCFs. This is in accordance with a study among 60&#x000a0;746 older people with depression, which reported a higher risk of stroke/transient ischemic attack, falls and fractures with mirtazapine and sertraline, versus no antidepressant use [<xref rid="ref19" ref-type="bibr">19</xref>]. No prior studies have investigated the comparative risk of dementia-, delirium- or cardiovascular-related hospitalisations among mirtazapine or sertraline users in LTCFs. A higher risk of falls associated with SSRIs, but not with mirtazapine or other antidepressants, has been reported [<xref rid="ref41" ref-type="bibr">41&#x02013;43</xref>], with risk higher at treatment initiation or dose changes [<xref rid="ref43" ref-type="bibr">43</xref>, <xref rid="ref44" ref-type="bibr">44</xref>]. A target trial emulation study following 101&#x000a0;953 older adults found mirtazapine and sertraline were associated with a lower risk of falls and related injuries in 1&#x000a0;year compared to no treatment (antidepressant or psychological therapy), and there were no differences in falls between these antidepressants [<xref rid="ref45" ref-type="bibr">45</xref>]. Our study similarly found no short-term differences in falls or fractures between mirtazapine and sertraline. However, the observed lower risk of falls and fractures associated with mirtazapine compared to sertraline after 90&#x000a0;days, together with findings from LTCF studies [<xref rid="ref20" ref-type="bibr">20</xref>, <xref rid="ref41" ref-type="bibr">41</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref44" ref-type="bibr">44</xref>], suggests the underlying mechanism for falls and fractures in the longer-term may differ between these agents. This warrants further investigation, alongside the potential contribution of prescribing cascades, such as changes (e.g. co-prescribing or deprescribing) in use of other psychotropic or sedating medicines [<xref rid="ref43" ref-type="bibr">43</xref>], and administration timing (e.g. mirtazapine taken at bedtime) [<xref rid="ref20" ref-type="bibr">20</xref>] to the risk of antidepressant-related adverse outcomes in LTCFs.</p><p>There are important clinical factors not measured in this study that may influence antidepressant choice and the risk of adverse outcomes. These include untreated depression, changes in mood, behaviour, sleep or weight, sarcopenia, hyponatremia, orthostatic hypotension and sedation [<xref rid="ref20" ref-type="bibr">20</xref>, <xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref46" ref-type="bibr">46</xref>]. In LTCFs, mirtazapine is commonly prescribed at subtherapeutic doses for depression [<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref47" ref-type="bibr">47</xref>] (i.e. where it is most sedating [<xref rid="ref8" ref-type="bibr">8</xref>]), thus may be used for sedation rather than treatment of moderate&#x02013;severe major depression. Minimal, mild and moderate depressive symptoms are experienced by 97% of new residents with depression [<xref rid="ref6" ref-type="bibr">6</xref>]. Prescribers&#x02019; decisions to select one antidepressant over another are often guided by safety profiles and existing prescribing experience [<xref rid="ref48" ref-type="bibr">48</xref>]. Residents&#x02019; low weight often drives preference for mirtazapine [<xref rid="ref7" ref-type="bibr">7</xref>], as weight gain is a common side effect. Our study included residents initiating an antidepressant within 2&#x000a0;months of LTCF entry, which may not be sufficient time for residents&#x02019; new healthcare practitioners to screen, identify and diagnose moderate&#x02013;severe major depression. It is likely that mirtazapine may be used for other indications (e.g. sleep, weight, low mood, symptoms of dementia), which are not supported by evidence for effectiveness [<xref rid="ref7" ref-type="bibr">7&#x02013;9</xref>]. The findings of this study highlight the risk of harm associated with mirtazapine use in LTCFs, providing new evidence to optimise person-centred, evidence-based therapeutic approaches to support resident mental health and wellbeing.</p><sec id="sec27"><title>Strengths and limitations</title><p>This is the first population-level study to examine risk of adverse outcomes associated with mirtazapine compared to sertraline in LTCFs. An active new user study design with propensity score adjustments was employed to minimise biases. Our linked data source facilitated comprehensive capture of potential confounders to be included in propensity score calculations and consideration for the competing risk of death, which is methodologically important in studies among residents of LTCFs, who are often approaching end-of-life [<xref rid="ref49" ref-type="bibr">49</xref>]. Additionally, both as-treated and intention-to-treat approaches were conducted to rule out selection bias or exposure misclassification [<xref rid="ref25" ref-type="bibr">25</xref>]. We included individuals entering LTCFs in three of Australia&#x02019;s largest states (78% of Australia&#x02019;s LTCF population [<xref rid="ref1" ref-type="bibr">1</xref>]) and thus findings are likely nationally representative and internationally generalisable to countries with similar aged care systems.</p><p>Limitations include potential for unmeasured confounding, which could be related to clinical information around antidepressant administration, indication, doses, depression severity and sedation, which are not available in the datasets used. Under-ascertainment of health conditions is also possible when claims data are used. The time-varying nature of covariates could not be examined as many were obtained from care assessments conducted at care entry and not routinely repeated afterwards. Outcomes were measured from hospital, emergency and death data collections and represent more critical incidents. This study compared risk of adverse outcomes between two antidepressants and did not look at no antidepressant or nonpharmacological use due to data availability and low uptake of these services (&#x0003c;3% of residents receive government-subsidised mental health services [<xref rid="ref50" ref-type="bibr">50</xref>]).</p></sec></sec><sec id="sec28"><title>Conclusions</title><p>This real-world study raises concern about the potential increased risk of harm associated with mirtazapine use in LTCFs, which is used by one in five residents. It supports the need for clinicians to consider safer alternatives in LTCFs and the place of antidepressants in treatment pathways, given 60% of residents use an antidepressant. This study highlights the need to regularly review and monitor antidepressant safety and effectiveness among residents using these medicines and to consider discontinuation and/or nonpharmacological alternatives where appropriate.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data"><label>aa-24-2498-File002_afaf074</label><media xlink:href="aa-24-2498-file002_afaf074.docx"/></supplementary-material></sec></body><back><ack id="afaf074-ack"><title>Acknowledgements</title><p>We would like to acknowledge Registry of Senior Australians&#x02019; (ROSA) Steering Committee, Consumer and Community Advisory Committee, Aboriginal and Torres Strait Islander Advisory Committee and ROSA Research Centre team based at the South Australian Health and Medical Research Institute (SAHMRI) and the Caring Futures Institute, College of Nursing and Health Sciences Flinders University for ensuring the success of the ROSA project. We also acknowledge the South Australian Government Department for Innovation and Skills (2017&#x02013;2021) who provided us with support to establish ROSA, the Australian Government Medical Research Future Fund (2021&#x02013;2024, PHRDI000009) and ROSA collaborating partners (SAHMRI, ECH Inc., Silver Chain, Life Care, Bolton Clark) for its ongoing support and the Australian Institute of Health and Welfare for the linkage and construction of input data, NSW Ministry of Health, VIC Department of Health (DH) and QLD Health for the provision of the state-based admitted and emergency department data used in the ROSA with linkage via the AIHW, Centre for Health Record Linkage (CHeReL), the Centre for Victorian Data Linkage (CVDL) and Queensland Health&#x02019;s Statistical Services Branch. We also acknowledge Anna Sheppeard, Consumer Advocate, for informing research priorities and comments on study findings.</p></ack><sec sec-type="COI-statement" id="sec29"><title>Declaration of Conflicts of Interest</title><p>J.K.S. is a nonexecutive director of Southern Cross Care SA, NT, VIC (an aged care provider organisation). There are no other conflicts of interest to declare.</p></sec><sec id="sec30"><title>Declaration of Sources of Funding</title><p>G.A.H. is supported by an Australian Government Research Training Program Scholarship. M.C.I. is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (GNT119378). G.E.C. is supported by an NHMRC Investigator Grant (GNT2026400). J.K.S. is supported by an NHMRC Investigator Grant (GNT2016277).</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hughes</surname> &#x000a0;<given-names>GA</given-names></string-name>, <string-name><surname>Inacio</surname> &#x000a0;<given-names>MC</given-names></string-name>, <string-name><surname>Rowett</surname> &#x000a0;<given-names>D</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>National trends in antidepressant use in Australian residential aged care facilities (2006&#x02013;2019)</article-title>. <source>J Am Med Dir Assoc</source>. <year>2024</year>;<volume>25</volume>:<fpage>104957</fpage>. <pub-id pub-id-type="doi">10.1016/j.jamda.2024.01.026</pub-id>.<pub-id pub-id-type="pmid">38432647</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Harris</surname> &#x000a0;<given-names>DA</given-names></string-name>, <string-name><surname>Maclagan</surname> &#x000a0;<given-names>LC</given-names></string-name>, <string-name><surname>Iaboni</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Potential unintended consequences of antipsychotic reduction in Ontario nursing homes</article-title>. <source>J Am Med Dir Assoc</source>. <year>2022</year>;<volume>23</volume>:<fpage>1066</fpage>&#x02013;<lpage>72.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jamda.2021.12.043</pub-id>.<pub-id pub-id-type="pmid">35143749</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Potteg&#x000e5;rd</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Lundby</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Ejg Jarb&#x000f8;l</surname> &#x000a0;<given-names>D</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Use of sedating medications around nursing home admission in Denmark</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2021</year>;<volume>30</volume>:<fpage>1560</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/pds.5341</pub-id>.<pub-id pub-id-type="pmid">34382278</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>Therapeutic Guidelines Limited</collab>
</person-group>. <source>Major Depression</source>. <comment>Therapeutic Guidelines Limited, 2021. <ext-link xlink:href="https://tgldcdp.tg.org.au/viewTopic?etgAccess=true%26#x0026;guidelinePage=Psychotropic%26#x0026;topicfile=major-depression%26#x0026;guidelinename=Psychotropic%26#x0026;sectionId=toc_d1e122#toc_d1e122" ext-link-type="uri">https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&#x00026;guidelinePage=Psychotropic&#x00026;topicfile=major-depression&#x00026;guidelinename=Psychotropic&#x00026;sectionId=toc_d1e122#toc_d1e122</ext-link> (31 January 2024, date last accessed)</comment>.</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bourgeois</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Elseviers</surname> &#x000a0;<given-names>MM</given-names></string-name>, <string-name><surname>Van Bortel</surname> &#x000a0;<given-names>L</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The use of antidepressants in Belgian nursing homes</article-title>. <source>Drugs Aging</source>. <year>2012</year>;<volume>29</volume>:<fpage>759</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1007/s40266-012-0003-6</pub-id>.<pub-id pub-id-type="pmid">23018612</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yuan</surname> &#x000a0;<given-names>Y</given-names></string-name>, <string-name><surname>Lapane</surname> &#x000a0;<given-names>KL</given-names></string-name>, <string-name><surname>Rothschild</surname> &#x000a0;<given-names>AJ</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Changes in depressive symptoms and cognitive impairment in older long-stay nursing home residents in the USA: a latent transition analysis</article-title>. <source>Aging Ment Health</source>. <year>2021</year>;<volume>25</volume>:<fpage>1903</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1080/13607863.2020.1849021</pub-id>.<pub-id pub-id-type="pmid">33222506</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gardner</surname> &#x000a0;<given-names>ME</given-names></string-name>, <string-name><surname>Malone</surname> &#x000a0;<given-names>DC</given-names></string-name>, <string-name><surname>Sey</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities</article-title>. <source>J Am Med Dir Assoc</source>. <year>2004</year>;<volume>5</volume>:<fpage>101</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S1525-8610(04)70063-8</pub-id>.<pub-id pub-id-type="pmid">14984621</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Watanabe</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Omori</surname> &#x000a0;<given-names>IM</given-names></string-name>, <string-name><surname>Nakagawa</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Mirtazapine versus other antidepressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source>. 2011;<volume>12</volume>:CD006528. <pub-id pub-id-type="doi">10.1002/14651858.CD006528.pub2</pub-id>.</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>The Guideline Development Group</collab>
</person-group>. <source><italic toggle="yes">Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and in Residential Aged Care</italic></source>. <publisher-loc>Parkville</publisher-loc>: <publisher-name>Monash University</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nelson</surname> &#x000a0;<given-names>JCMD</given-names></string-name>, <string-name><surname>Delucchi</surname> &#x000a0;<given-names>KP</given-names></string-name>, <string-name><surname>Schneider</surname> &#x000a0;<given-names>LSMD</given-names></string-name></person-group>. <article-title>Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2008</year>;<volume>16</volume>:<fpage>558</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1097/01.JGP.0000308883.64832.ed</pub-id>.<pub-id pub-id-type="pmid">18591576</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kok</surname> &#x000a0;<given-names>RM</given-names></string-name>, <string-name><surname>Nolen</surname> &#x000a0;<given-names>WA</given-names></string-name>, <string-name><surname>Heeren</surname> &#x000a0;<given-names>TJ</given-names></string-name></person-group>. <article-title>Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants</article-title>. <source>J Affect Disord</source>. <year>2012</year>;<volume>141</volume>:<fpage>103</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2012.02.036</pub-id>.<pub-id pub-id-type="pmid">22480823</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boyce</surname> &#x000a0;<given-names>RD</given-names></string-name>, <string-name><surname>Hanlon</surname> &#x000a0;<given-names>JT</given-names></string-name>, <string-name><surname>Karp</surname> &#x000a0;<given-names>JF</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>A review of the effectiveness of antidepressant medications for depressed nursing home residents</article-title>. <source>J Am Med Dir Assoc</source>. <year>2012</year>;<volume>13</volume>:<fpage>326</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.jamda.2011.08.009</pub-id>.<pub-id pub-id-type="pmid">22019084</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mottram</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Wilson</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Strobl</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressants for depressed elderly</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>; <volume>2006</volume>:<fpage>CD003491</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD003491.pub2</pub-id>.<pub-id pub-id-type="pmid">16437456</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Halikas</surname> &#x000a0;<given-names>J</given-names></string-name>
</person-group>. <article-title>Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients</article-title>. <source>Hum Psychopharmacol</source>. <year>1995</year>;<volume>10</volume>:<fpage>S125</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/hup.470100807</pub-id>.</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hsy&#x000f8;erg</surname> &#x000a0;<given-names>OJ</given-names></string-name>, <string-name><surname>Maragakis</surname> &#x000a0;<given-names>B</given-names></string-name>, <string-name><surname>Mullin</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients</article-title>. <source>Acta Psychiatr Scand</source>. <year>1996</year>;<volume>93</volume>:<fpage>184</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0447.1996.tb10629.x</pub-id>.<pub-id pub-id-type="pmid">8739664</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schatberg</surname> &#x000a0;<given-names>AF</given-names></string-name>, <string-name><surname>Kremer</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Rodrigues</surname> &#x000a0;<given-names>HE</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2002</year>;<volume>10</volume>:<fpage>541</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1097/00019442-200209000-00007</pub-id>.<pub-id pub-id-type="pmid">12213688</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Banerjee</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Farina</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Henderson</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer&#x02019;s disease and agitated behaviours: the HTA-SYMBAD trial</article-title>. <source>Health Technol Assess</source>. <year>2023</year>;<volume>27</volume>:<fpage>1</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.3310/VPDT7105</pub-id>.</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Banerjee</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Hellier</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Dewey</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>:<fpage>403</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60830-1</pub-id>.<pub-id pub-id-type="pmid">21764118</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Coupland</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Dhiman</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Morriss</surname> &#x000a0;<given-names>R</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressant use and risk of adverse outcomes in older people: population based cohort study</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>343</volume>:<fpage>d4551</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.d4551</pub-id>.<pub-id pub-id-type="pmid">21810886</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gagne</surname> &#x000a0;<given-names>JJ</given-names></string-name>, <string-name><surname>Patrick</surname> &#x000a0;<given-names>AR</given-names></string-name>, <string-name><surname>Mogun</surname> &#x000a0;<given-names>H</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressants and fracture risk in older adults: a comparative safety analysis</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>89</volume>:<fpage>880</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2011.54</pub-id>.<pub-id pub-id-type="pmid">21508938</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kollhorst</surname> &#x000a0;<given-names>B</given-names></string-name>, <string-name><surname>Jobski</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Krappweis</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressants and the risk of death in older patients with depression: a population-based cohort study</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>:<fpage>e0215289</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0215289</pub-id>.<pub-id pub-id-type="pmid">30986235</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roose</surname> &#x000a0;<given-names>SP</given-names></string-name>, <string-name><surname>Nelson</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Salzman</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Mirtazapine in the nursing home study group. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home</article-title>. <source>Curr Med Res Opin</source>. <year>2003</year>;<volume>19</volume>:<fpage>737</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1185/030079903125002441</pub-id>.<pub-id pub-id-type="pmid">14687445</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nelson</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Hollander</surname> &#x000a0;<given-names>SB</given-names></string-name>, <string-name><surname>Betzel</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2006</year>;<volume>21</volume>:<fpage>898</fpage>&#x02013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1002/gps.1589</pub-id>.<pub-id pub-id-type="pmid">16955423</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nelson</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Holden</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Roose</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?</article-title> &#x000a0;<source>Int J Geriatr Psychiatry</source>. <year>2007</year>;<volume>22</volume>:<fpage>999</fpage>&#x02013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1002/gps.1779</pub-id>.<pub-id pub-id-type="pmid">17447229</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lund</surname> &#x000a0;<given-names>JL</given-names></string-name>, <string-name><surname>Richardson</surname> &#x000a0;<given-names>DB</given-names></string-name>, <string-name><surname>Sturmer</surname> &#x000a0;<given-names>T</given-names></string-name></person-group>. <article-title>The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application</article-title>. <source>Curr Epidemiol Rep</source>. <year>2015</year>;<volume>2</volume>:<fpage>221</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s40471-015-0053-5</pub-id>.<pub-id pub-id-type="pmid">26954351</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Inacio</surname> &#x000a0;<given-names>MC</given-names></string-name>, <string-name><surname>Caughey</surname> &#x000a0;<given-names>GE</given-names></string-name>, <string-name><surname>Wesselingh</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Registry of Senior Australians (ROSA): integrating cross-sectoral information to evaluate quality and safety of care provided to older people</article-title>. <source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>:<fpage>e066390</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2022-066390</pub-id>.</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>World Health Organization Collaborating Centre for Drug Statistics Methodology</collab>
</person-group>. <source>ATC/DDD Index 2024</source>. <comment>Norwegian Institute of Public Health, 2024. <ext-link xlink:href="https://atcddd.fhi.no/atc_ddd_index/" ext-link-type="uri">https://atcddd.fhi.no/atc_ddd_index/</ext-link> (1 October 2024, date last accessed)</comment>.</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Inacio</surname> &#x000a0;<given-names>MC</given-names></string-name>, <string-name><surname>Lang</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Caughey</surname> &#x000a0;<given-names>GE</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The Registry of Senior Australians outcome monitoring system: quality and safety indicators for residential aged care</article-title>. <source>Int J Qual Health Care</source>. <year>2020</year>;<volume>32</volume>:<fpage>502</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/intqhc/mzaa078</pub-id>.<pub-id pub-id-type="pmid">32696038</pub-id>
</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sluggett</surname> &#x000a0;<given-names>JK</given-names></string-name>, <string-name><surname>Caughey</surname> &#x000a0;<given-names>GE</given-names></string-name>, <string-name><surname>Ward</surname> &#x000a0;<given-names>MB</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data</article-title>. <source>BMC Res Notes</source>. <year>2013</year>;<volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1186/1756-0500-6-128</pub-id>.<pub-id pub-id-type="pmid">23281703</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sharma</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Wood</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Bell</surname> &#x000a0;<given-names>JS</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study</article-title>. <source>Lancet Reg Health West Pac</source>. <year>2023</year>;<volume>33</volume>:<fpage>100692</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanwpc.2023.100692</pub-id>.<pub-id pub-id-type="pmid">37181530</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lu</surname> &#x000a0;<given-names>CY</given-names></string-name>, <string-name><surname>Roughead</surname> &#x000a0;<given-names>E</given-names></string-name></person-group>. <article-title>New users of antidepressant medications: first episode duration and predictors of discontinuation</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2012</year>;<volume>68</volume>:<fpage>65</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-011-1087-3</pub-id>.<pub-id pub-id-type="pmid">21713518</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Potteg&#x000e5;rd</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Hallas</surname> &#x000a0;<given-names>J</given-names></string-name></person-group>. <article-title>Assigning exposure duration to single prescriptions by use of the waiting time distribution</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2013</year>;<volume>22</volume>:<fpage>803</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/pds.3459</pub-id>.<pub-id pub-id-type="pmid">23703741</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pratt</surname> &#x000a0;<given-names>NL</given-names></string-name>, <string-name><surname>Kerr</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Barratt</surname> &#x000a0;<given-names>JD</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The validity of the Rx-risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system</article-title>. <source>BMJ Open</source>. <year>2018</year>;<volume>8</volume>:<fpage>e021122</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2017-021122</pub-id>.</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Allan</surname> &#x000a0;<given-names>V</given-names></string-name>, <string-name><surname>Ramagopalan</surname> &#x000a0;<given-names>SV</given-names></string-name>, <string-name><surname>Mardekian</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants</article-title>. <source>J Comp Eff Res</source>. <year>2020</year>;<volume>9</volume>:<fpage>603</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.2217/cer-2020-0013</pub-id>.<pub-id pub-id-type="pmid">32186922</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fine</surname> &#x000a0;<given-names>JP</given-names></string-name>, <string-name><surname>Gray</surname> &#x000a0;<given-names>RJ</given-names></string-name></person-group>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source>. <year>1999</year>;<volume>94</volume>:<fpage>496</fpage>&#x02013;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id>.</mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>International Consortium for Health Outcomes Measurement</collab>
</person-group>. <source>Patient-Centred Outcome Measures Sets</source>. <comment>ICHOM, 2024. <ext-link xlink:href="https://www.ichom.org/patient-centered-outcome-measures/#standard-sets" ext-link-type="uri">https://www.ichom.org/patient-centered-outcome-measures/#standard-sets</ext-link> (11 October 2024, date last accessed)</comment>.</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Danielsson</surname> &#x000a0;<given-names>B</given-names></string-name>, <string-name><surname>Collin</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Jonasdottir Bergman</surname> &#x000a0;<given-names>G</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults&#x02014;a Swedish Nationwide study</article-title>. <source>Br J Clin Pharmacol</source>. <year>2016</year>;<volume>81</volume>:<fpage>773</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.12829</pub-id>.<pub-id pub-id-type="pmid">26574175</pub-id>
</mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cai</surname> &#x000a0;<given-names>W</given-names></string-name>, <string-name><surname>Mueller</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Shetty</surname> &#x000a0;<given-names>H</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Predictors of mortality in people with late-life depression: a retrospective cohort study</article-title>. <source>J Affect Disord</source>. <year>2020</year>;<volume>266</volume>:<fpage>695</fpage>&#x02013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2020.01.021</pub-id>.<pub-id pub-id-type="pmid">32056946</pub-id>
</mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Joseph</surname> &#x000a0;<given-names>RM</given-names></string-name>, <string-name><surname>Jack</surname> &#x000a0;<given-names>RH</given-names></string-name>, <string-name><surname>Morriss</surname> &#x000a0;<given-names>R</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records</article-title>. <source>BMC Med</source>. <year>2022</year>;<volume>20</volume>:<fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-022-02247-x</pub-id>.<pub-id pub-id-type="pmid">35105363</pub-id>
</mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>Australian Government Department of Health and Aged Care</collab>
</person-group>. <source><italic toggle="yes">Pharmaceutical Benefits Scheme (PBS) Expenditure and Prescriptions Report 1 July 2022 to 30 June 2023</italic></source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>Commonwealth of Australia</publisher-name>, <year>2023</year>.</mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Macri</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Iaboni</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Kirkham</surname> &#x000a0;<given-names>JG</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Association between antidepressants and fall-related injuries among long-term care residents</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2017</year>;<volume>25</volume>:<fpage>1326</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.jagp.2017.08.014</pub-id>.<pub-id pub-id-type="pmid">28943234</pub-id>
</mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Inacio</surname> &#x000a0;<given-names>MC</given-names></string-name>, <string-name><surname>Moldovan</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Whitehead</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The risk of fall-related hospitalisations at entry into permanent residential aged care</article-title>. <source>BMC Geriatr</source>. <year>2021</year>;<volume>21</volume>:<fpage>686</fpage>. <pub-id pub-id-type="doi">10.1186/s12877-021-02640-w</pub-id>.<pub-id pub-id-type="pmid">34876037</pub-id>
</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sterke</surname> &#x000a0;<given-names>CS</given-names></string-name>, <string-name><prefix>van</prefix> &#x000a0;<surname>Beeck</surname> &#x000a0;<given-names>EF</given-names></string-name>, <string-name><prefix>van der</prefix> &#x000a0;<surname>Velde</surname> &#x000a0;<given-names>N</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>New insights: dose-response relationship between psychotropic drugs and falls: a study in nursing home residents with dementia</article-title>. <source>J Clin Pharmacol</source>. <year>2012</year>;<volume>52</volume>:<fpage>947</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1177/0091270011405665</pub-id>.<pub-id pub-id-type="pmid">21628599</pub-id>
</mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Berry</surname> &#x000a0;<given-names>SD</given-names></string-name>, <string-name><surname>Zhang</surname> &#x000a0;<given-names>Y</given-names></string-name>, <string-name><surname>Lipsitz</surname> &#x000a0;<given-names>LA</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Antidepressant prescriptions: an acute window for falls in the nursing home</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2011</year>;<volume>66A</volume>:<fpage>1124</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/glr113</pub-id>.</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname> &#x000a0;<given-names>GH</given-names></string-name>, <string-name><surname>Lai</surname> &#x000a0;<given-names>EC</given-names></string-name>, <string-name><surname>Goodin</surname> &#x000a0;<given-names>AJ</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Injurious fall risk differences among older adults with first-line depression treatments</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>:<fpage>e2435535</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.35535</pub-id>.<pub-id pub-id-type="pmid">39186265</pub-id>
</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<prefix>van</prefix> &#x000a0;<surname>Poelgeest</surname> &#x000a0;<given-names>EP</given-names></string-name>, <string-name><surname>Pronk</surname> &#x000a0;<given-names>AC</given-names></string-name>, <string-name><surname>Rhebergen</surname> &#x000a0;<given-names>D</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Depression, antidepressants and fall risk: therapeutic dilemmas&#x02014;a clinical review</article-title>. <source>Eur Geriatr Med</source>. <year>2021</year>;<volume>12</volume>:<fpage>585</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1007/s41999-021-00475-7</pub-id>.<pub-id pub-id-type="pmid">33721264</pub-id>
</mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nishtala</surname> &#x000a0;<given-names>PS</given-names></string-name>, <string-name><surname>McLachlan</surname> &#x000a0;<given-names>AJ</given-names></string-name>, <string-name><surname>Bell</surname> &#x000a0;<given-names>SJ</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Determinants of antidepressant medication prescribing in elderly residents of aged care homes in Australia: a retrospective study</article-title>. <source>Am J Geriatr Pharmacother</source>. <year>2009</year>;<volume>7</volume>:<fpage>210</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjopharm.2009.07.001</pub-id>.<pub-id pub-id-type="pmid">19766953</pub-id>
</mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gardner</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>MacKinnon</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Langille</surname> &#x000a0;<given-names>DB</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>A comparison of factors used by physicians and patients in the selection of antidepressant agents</article-title>. <source>Psychiatr Serv</source>. <year>2007</year>;<volume>58</volume>:<fpage>34</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ps.58.1.34</pub-id>.<pub-id pub-id-type="pmid">17215410</pub-id>
</mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sluggett</surname> &#x000a0;<given-names>JK</given-names></string-name>, <string-name><surname>Inacio</surname> &#x000a0;<given-names>MC</given-names></string-name>, <string-name><surname>Caughey</surname> &#x000a0;<given-names>GE</given-names></string-name></person-group>. <article-title>Medication management in long-term care: using evidence generated from real-world data to effect policy change in the Australian setting</article-title>. <source>Am J Epidemiol</source>. <year>2024</year>;<volume>193</volume>:<fpage>1645</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwae136</pub-id>.<pub-id pub-id-type="pmid">38896047</pub-id>
</mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cations</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Collier</surname> &#x000a0;<given-names>LR</given-names></string-name>, <string-name><surname>Caughey</surname> &#x000a0;<given-names>G</given-names></string-name> &#x000a0;<etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Government-subsidised mental health services are underused in Australian residential aged care facilities</article-title>. <source>Aust Health Rev</source>. <year>2022</year>;<volume>46</volume>:<fpage>432</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1071/AH22049</pub-id>.<pub-id pub-id-type="pmid">35772928</pub-id>
</mixed-citation></ref></ref-list></back></article>